Accueil   Diary - News   All news Adocia announces positive topline results for the first clinical study of ADO09

Adocia announces positive topline results for the first clinical study of ADO09

 

 

  • ADO09 is the first co-formulation of pramlintide and the rapid-acting A21G human insulin analog, the metabolite of insulin glargine
  • ADO09 showed a significant 85% decrease in blood glucose excursion over the first two hours after a meal compared to Humalog®
  • ADO09 showed similar glucose control over the first two hours after a meal compared to separate injections of Symlin® and Humulin®
  • All treatments were well tolerated

 

 

Lyon, France, April 9th, 2019 – 6:00 pm CET - Adocia (Euronext Paris: FR0011184241 – ADOC) the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of approved proteins, announces today positive topline pharmacodynamic and safety results from the first Phase 1 study of ADO09, a ready-to-use, pH 4, co-formulation at fixed ratio of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog (“A21G human insulin”), a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine (Lantus®, Sanofi). A21G human insulin is considered to be safe, as millions of people using insulin glargine are routinely exposed to it1. ADO09 is an innovative formulation for which Adocia has filed an international patent application.

 

Read the press release